Sign Out
1 dose (0.5 mL) contains: Human Papillomavirus type 16 L1 protein1 20 micrograms, Human Papillomavirus type 18 L1 protein1 20 micrograms, 3-O-desacyl-4'-monophosphoryl lipid A (MPL)2 50 micrograms, Hydrated aluminium hydroxide2 0.5 milligrams Al3+.
1L1 protein in the form of non-infectious virus-like particles (VLPs) produced by recombinant DNA technology using a Baculovirus expression system.
2The GlaxoSmithKline proprietary AS04 adjuvant system is composed of aluminium hydroxide and 3-O-desacyl-4'-monophosphoryl lipid A (MPL) (see Pharmacology: Pharmacodynamics under Actions).
